Article
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
ESMO open - 1 Dec 2023
Westphalen C B, Federer-Gsponer J, Pauli C, Karapetyan A R, Chalabi N, Durán-Pacheco G, Beringer A, Bochtler T, Cook N, Höglander E, Jin D X, Losa F, Mileshkin L, Moch H, Ross J S, Sokol E S, Tothill R W, Krämer A
Abstract excerpt
BACKGROUND: Patients with unfavorable carcinoma of unknown primary origin (CUP) have an extremely poor prognosis of ∼1 year or less, stressing the need for more tailored treatments, which are currently being tested in clinical trials. CUPISCO (NCT03498521) was a phase II randomized study of targeted therapy/cancer immunotherapy versus platinum-based chemotherapy in patients with previously untreated, unfavorable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.